Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00287027 |
Recruitment Status :
Terminated
First Posted : February 6, 2006
Last Update Posted : January 5, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Psychotic Disorders | Drug: Risperdal Long Acting Injectable Antipsychotic Medication |
Study Type : | Observational |
Enrollment : | 60 participants |
Observational Model: | Defined Population |
Time Perspective: | Prospective |
Official Title: | Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication |
Study Start Date : | February 2006 |
Study Completion Date : | December 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Inclusion criteria:Families of adults between the ages of 18-65 who have a diagnosis of Schizophrenia, Schizoaffective Disorder, Psychotic Disorder NOS, and whose loved one gave permission for them to be contacted.
- Either a) a family member whose adult consumer started on Risperidone Long Acting Injection within one month, while at New Hampshire Hospital and/or at a Community Mental Health Center and who consented to participate; or b) a family member whose adult consumer was switched from one antipsychotic medication to another (excluding clozapine) within one month, while at New Hampshire Hospital and/or at a Community Mental Health Center and who consented to participate.
- Families that have at least 4 hours per week contact with their loved one with mental illness for 2 of the 4 weeks preceding the medication change.
Exclusion Criteria:
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00287027
United States, New Hampshire | |
NAMI NH | |
Concord, New Hampshire, United States, 03301 |
Principal Investigator: | Alex deNesnera, MD | Dartmouth-Hitchcock Medical Center |
ClinicalTrials.gov Identifier: | NCT00287027 |
Other Study ID Numbers: |
CPHS#17558 |
First Posted: | February 6, 2006 Key Record Dates |
Last Update Posted: | January 5, 2007 |
Last Verified: | January 2007 |
psychotic disorders family burden long acting injectible antipsychotic medication |
Mental Disorders Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders Antipsychotic Agents |
Physiological Effects of Drugs Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs |